Larimar Therapeutics, Inc. (LRMR)

USD 4.16

(-3.7%)

Market Cap (In USD)

265.43 Million

Revenue (In USD)

-

Net Income (In USD)

-36.94 Million

Avg. Volume

575.77 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.01-13.68
PE
-
EPS
-
Beta Value
0.713
ISIN
US5171251003
CUSIP
517125100
CIK
1374690
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Carole S. Ben-Maimon M.D.
Employee Count
-
Website
https://www.larimartx.com
Ipo Date
2014-06-19
Details
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.